Stock Performance Review on Medical Laboratories & Research Industry -- Cancer Genetics, BioTelemetry, Organovo, and Bruker

Tuesday, August 1, 2017 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, August 1, 2017 /PRNewswire/ --

If you want a Stock Review on CGIX, BEAT, ONVO or BRKR then come over to and sign up for your free customized report today. On Monday, the NASDAQ Composite ended the day at 6,348.12, down 0.42%; the Dow Jones Industrial Average edged 0.28% higher, to finish at 21,891.12; and the
S&P 500 closed at 2,470.30, marginally slipping 0.07%. US markets saw a mixed session as 4 sectors closed in green, 4 sectors finished in red, and 1 sector ended flat for the day. has initiated research reports on the following Medical Laboratories & Research stocks: Cancer Genetics Inc. (NASDAQ: CGIX), BioTelemetry Inc. (NASDAQ: BEAT), Organovo Holdings Inc. (NASDAQ: ONVO), and Bruker Corp. (NASDAQ: BRKR). Daily Stock Tracker published comprehensive and free research reports on these stocks today at:

Cancer Genetics 

Rutherford, New Jersey-based Cancer Genetics Inc.'s stock finished Monday's session 1.33% lower at $3.70 with a total trading volume of 32,122 shares. The stock has gained 88.78% in the previous twelve months and 174.07% since the start of this year. Shares of the Company are trading above their 200-day moving averages by 34.72%. Moreover, shares of Cancer Genetics, which develops, commercializes, and provides molecular and biomarker-based tests and services in the US, India, and China, have a Relative Strength Index (RSI) of 43.20. CGIX complete research report is just a click away and free at:


Shares in Malvern, Pennsylvania headquartered BioTelemetry Inc. declined 1.72%, ending yesterday's session at $34.20 with a total trading volume of 294,032 shares. The stock has gained 6.71% in the past month, 79.81% over the past twelve months, and 53.02% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 9.97% and 32.81%, respectively. Moreover, shares of BioTelemetry, which provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services, have an RSI of 56.78.

On July 19th, 2017, research firm The Benchmark Company reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $38 a share to $44 a share. The complimentary report on BEAT can be downloaded at:


On Monday, San Diego, California headquartered Organovo Holdings Inc.'s stock ended the day flat at $2.34. A total volume of 430,858 shares was traded. The stock is trading below its 50-day moving average by 12.52%. Additionally, shares of Organovo Holdings, which focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs, have an RSI of 28.46.  Sign up for your complimentary research report on ONVO at:


Shares in Billerica, Massachusetts headquartered Bruker Corp. ended the day 1.31% higher at $28.68. A total volume of 403,036 shares was traded. The stock has gained 16.49% in the previous three months, 15.09% over the last twelve months, and 35.41% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 1.77% and 18.27%, respectively. Furthermore, shares of Bruker, which develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions worldwide, have an RSI of 50.98.

On July 13th, 2017, research firm Wells Fargo downgraded the Company's stock rating from 'Market Perform' to 'Underperform'. Get free access to your research report on BRKR at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store